A NEW treatment for locally
advanced basal cell carcinoma
(laBCC) called Odomzo (sonidegib)
from Novartis has been approved
by the US Food and Drug
Administration.
Other drugs passing muster were
Daklinza (daclatasvir) for hepatitis
C virus (HCV) genotype 3, and
Praluent (alirocumab) injection, the
first of a new cholesterol-lowering
class of drugs known as proprotein
convertase subtilisin kexin type 9
(PCSK9) inhibitors.The above article was sent to subscribers in Pharmacy Daily's issue from 28 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Jul 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.